thiazoles has been researched along with Bladder, Overactive in 356 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.28) | 29.6817 |
| 2010's | 258 (72.47) | 24.3611 |
| 2020's | 97 (27.25) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, HJ; Cho, J; Foo, CY; Hadi, FA; Kang, D; Kim, S; Lee, KS; Park, H | 1 |
| Chaudhry, N; Kumar, A; Kumar, N; Nagendra Rao, S; Patel, S; Prasad, V; Vasudeva, P; Yadav, P; Yadav, S | 1 |
| Girman, CJ; Kennelly, MJ; Mudd, PN; Rhodes, T; Shortino, D; Thomas, E | 1 |
| Ma, J; Sun, K; Wang, D; Wang, J; Wang, T; Wu, G; Wu, J | 1 |
| Ariman, A; Çulha, MG; Merder, E | 1 |
| Yamanishi, T | 1 |
| Kuroishi, K; Mishima, Y; Takahashi, S; Ukai, M | 1 |
| Breinbjerg, A; Hagstrøm, S; Kamperis, K; Pedersen, N; Rittig, S; Thorsteinsson, K | 1 |
| Chakra, MA; Dabboucy, B; Dellis, A; Fares, Y; Moussa, M; Papatsoris, A | 1 |
| Yang, J; Yang, Y; Yi, W | 1 |
| Babu, R; Chadha, S; Chittibabu, T | 1 |
| Hennenberg, M; Huang, R; Stief, CG; Strittmatter, F; Tamalunas, A; Waidelich, R | 1 |
| Raker, CA; Sripad, AA; Sung, VW | 1 |
| Covernton, PJO; Martins de Almeida, R; Mateu Arrom, L; Mora Blazquez, AM; Ortíz Núñez, A | 1 |
| Ihara, T; Kira, S; Mitsui, T; Nakagomi, H; Sawada, N; Shimura, H; Takeda, M | 1 |
| Chen, Y; Dai, R; Deng, C | 1 |
| Brubaker, L; Halverson, T; Mueller, ER; Wolfe, AJ | 1 |
| Chen, SF; Chuang, YC; Kuo, HC; Liao, CH; Wang, CC | 1 |
| An, J; Cho, HJ; Hur, KJ; Jang, JA; Kim, JS; Kim, YJ; Kwon, J; Lee, EJ; Park, D; Park, HR; Yang, H; Yoshimura, N | 1 |
| Ito, H; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K | 1 |
| Chess-Williams, R; McDermott, C; Sellers, DJ; West, EG | 1 |
| Hsiao, SM; Lin, HH; Su, TC; Tu, FC; Wu, PC | 1 |
| Akkoc, Y | 1 |
| Dmochowski, R; Gleicher, S; Reynolds, WS; Sebesta, EM | 1 |
| Fukuhara, H; Kinjo, M; Masuda, K; Miyakawa, J; Nakamura, Y; Tambo, M | 1 |
| Gotoh, M; Matsukawa, Y | 1 |
| Chuang, YC; Lee, WC; Shen, YC; Wang, HJ; Wu, TH | 1 |
| Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O | 1 |
| Cardozo, L; Chapple, CR; Choudhury, N; Cruz, F; Heesakkers, J; Herschorn, S; Siddiqui, E; Staskin, D; Stoelzel, M | 1 |
| Inoue, M; Yokoyama, T | 1 |
| Jong, JJ; Kakizaki, H; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O | 1 |
| Engel, E; Herschorn, S; Kristy, RM; Schermer, CR; Staskin, D; Wagg, A | 1 |
| Marcelissen, T; Rademakers, K | 1 |
| Hizue, M; Ito, Y; Kadekawa, K; Nishijima, S; Sugaya, K; Yamada, S; Yamagami, H | 1 |
| Corbett, HJ; Dobson, E; Fryer, S; Griffiths, M; Kenny, SE; McAndrew, HF; Nicoara, C | 1 |
| Baka-Ostrowska, M; Bosman, B; Kjaeer, B; Passier, P; Rittig, S; Stroosma, O; Tannenbaum, S; Tøndel, C; Walle, JV | 1 |
| Kawahara, T | 1 |
| Cambronero Santos, J; Chapple, C; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT; Schermer, CR; Staskin, D | 1 |
| Kociszewski, J; Poleszak, E; Serefko, A; Szopa, A; Wiśniewski, R; Woźniak, A; Wróbel, A | 1 |
| Sahin, A; Urkmez, A; Yildirim, C; Yuksel, OH | 1 |
| Ader, M; Baskin, AS; Bergman, RN; Brychta, RJ; Cai, H; Cassimatis, TM; Cero, C; Chen, KY; Cypess, AM; Dieckmann, W; Fink, YA; Fletcher, LA; Herscovitch, P; Javitt, NB; Johnson, JW; Kapuria, D; Kelsey, N; Leitner, BP; Linderman, JD; McGehee, S; Millo, CM; O'Mara, AE; Piccinini, F; Rotman, Y; Sater, ZA; Walter, M; Walter, PJ | 1 |
| Fuse, M; Kaga, K; Kageyama, S; Sakata, K; Tokunaga, S; Yamanishi, T; Yokoyama, T | 1 |
| Chen, Z; Gao, Y; Liang, L; Lin, J; Liu, L; Su, S | 1 |
| Egberts, J; Elzevier, HW; Groenendijk, PM; Kummeling, MTM; Putter, H; van Koeveringe, GA | 1 |
| Araklitis, G; Baines, G; Cardozo, L; Flint, R; Robinson, D | 1 |
| Alothmani, R; Aronsson, P; Carlsson, T; Patel, B; Perez, F; Winder, M | 1 |
| Balsamo, R; Costantini, E; Finazzi Agrò, E; Illiano, E; Natale, F | 1 |
| Poza-Barrasús, JL; Valero Fernández, EM; Zubiaur Líbano, C | 1 |
| Campbell, NL; Elsouda, D; Griebling, TL; Herschorn, S; Mangel, J; Schermer, CR; Staskin, D | 1 |
| Peyronnet, B | 1 |
| Mandpe, P; Prabhakar, B; Shende, P | 1 |
| Aoki, H; Fujio, K; Hori, S; Kosaka, T; Otsuki, H; Uehara, S; Yamasaki, T | 1 |
| Gibson, W; Makhani, A; Thake, M | 1 |
| Baska, A; Gałązka, P; Leis, K; Mazur, E; Racinowski, M; Świerczyński, W | 1 |
| Chen, CH; Chuang, YC; Lee, WC; Shen, YC; Wang, HJ | 1 |
| Ikeuchi, T; Kikuchi, R; Okuyama, C | 1 |
| Athanasiou, S; Grigoriadis, T; Pitsouni, E; Salvatore, S; Serati, M; Zacharakis, D | 1 |
| Arlandis Guzmán, S; Blanco, N; Jiménez Cidre, MÁ; Landeira, M; Rubio-Rodríguez, D; Rubio-Terrés, C | 1 |
| Kwon, SY; Lee, KS; Park, DJ; Seo, YJ | 1 |
| Herschorn, S; Kristy, RM; Schermer, CR; Staskin, D; Wagg, A | 1 |
| Kato, D; Tabuchi, H; Takahashi, S; Uno, S | 1 |
| Burek, C; Corbetta, JP; Gomez, YR; Lopez Imizcoz, F; Ruiz, J; Sager, C; Sanmartino, M; Szklarz, T; Tessi, C; Vazquez Patiño, M; Weller, S | 1 |
| Brucker, BM; Charlson, ER; Enemchukwu, E; Howard, J; Jericevic, D; Krupp, L; Pape, D; Peyronnet, B; Rosenblum, N; Rude, T; Zhovtis-Ryerson, L | 1 |
| Hairston, J; Kraus, SR; Qian, C; Rogula, B; Shiozawa, A; Szabo, SM | 1 |
| El-Abd, AS; El-Abd, SA; Radwan, MH; Soliman, MG; Tawfik, AM | 1 |
| Chang, YS; Choo, MS; Kim, JC; Ko, KJ; Lee, KS | 1 |
| Araklitis, G; Cardozo, L; Robinson, D | 1 |
| Hairston, JC; Harrigan, S; Johnston, K; Kristy, RM; Lozano-Ortega, G; Mickle, A; Rogula, B; Schermer, CR; Walker, DR | 1 |
| Araklitis, G; Baines, G; Cardozo, L; da Silva, AS; Robinson, D | 1 |
| Ishida, K; Jong, JJ; Kakizaki, H; Katoh, T; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O | 1 |
| Ikeuchi, R; Koike, S; Okada, T; Soda, T; Tashiro, Y | 1 |
| Rechberger, T; Wróbel, A | 1 |
| Cambronero Santos, J; Choudhury, N; Foley, S; Hairston, J; Herschorn, S; Kaplan, SA; Kristy, RM; McVary, KT | 1 |
| Wein, AJ | 5 |
| Campeau, L; Fogaing, C; Mossa, AH | 1 |
| Kakizaki, H; Katou, D; Lee, KS; Sumarsono, B; Uno, S; Yamaguchi, O; Yamamoto, O | 1 |
| Barnes, H; Bennett, AT; Brown, OE; Cardenas-Trowers, OO; Chang, OH; Escobar, C; Falk, KN; Hall, EF; Jeney, SES; Mehta, S; Menhaji, K; Ringel, NE; Sappenfield, EC; Tellechea, LM | 1 |
| Cho, SY; Choo, MS; Jeong, SJ; Kim, J; Lee, S; Lee, SH; Oh, SJ | 1 |
| Kumar, N; Prasad, V; Prashanth, YM; Saurav, K; Tyagi, V; Vasudeva, P; Yadav, S | 1 |
| Kaplan, SA; Mullen, GR | 1 |
| Bílková, K; Borovička, V; Cífková, R; Krhut, J; Kufová, E; Mokriš, J; Pudich, J; Sýkora, R; Wohlfahrt, P; Zachoval, R; Zvara, P | 1 |
| Gambhire, M; Gambhire, V; Panchal, D; Raut, P | 1 |
| Selvi, I | 1 |
| Appenteng, K; Arana, A; Bahmanyar, S; de Vogel, S; Enger, C; Hallas, J; Hoffman, V; Horter, L; Kristiansen, NS; Linder, M; Margulis, A; Odsbu, I; Olesen, M; Perez-Gutthann, S; Phiri, K; Seeger, J; Suehs, B | 1 |
| Chimoto, J; Morikawa, K; Okura, T; Shiho, M; Shinozuka, K; Wakuda, H; Yamada, S | 1 |
| Aizawa, N; Fujimori, Y; Fujita, T; Goi, Y; Hayashi, T; Kobayashi, JI; Nakanishi, O | 1 |
| Behera, DP; Gupta, S; Singh, I; T K, A | 1 |
| Chae, C; Cheon, SH; Kim, SC; Kwon, T; Moon, KH; Park, M; Park, S; Yoon, JH | 1 |
| Hwang, YT; Kuo, HC; Lee, CL; Wang, CC | 1 |
| Carlson, KV; Deal, AS; Hairston, JC; Kristy, RM; Nair, KV; Rovner, ES | 1 |
| Abou-Ramadan, AR; El-Abd, AS; El-Abd, S; El-Gamal, OM; Raheem, AA; Soliman, MG | 1 |
| Furuhata, M; Hosaka, K; Ishizuka, O; Minagawa, T; Nakagawa, T; Ogawa, T; Saito, T; Suzuki, T | 1 |
| Keam, SJ | 1 |
| Baka-Ostrowska, M; Bolong, DT; Lademacher, C; Martin, N; Persu, C; Steup, A; Tøndel, C | 1 |
| Kellogg, D; Kelly, C; Koek, W; Kraus, S; Polk, M; Romo, T; Stowe, S; Trbovich, M | 1 |
| Burnett, AL; Karakus, S; Musicki, B | 1 |
| Appenteng, K; Arana, A; de Vogel, S; Enger, C; Hallas, J; Hoffman, V; Horter, L; Kristiansen, NS; Linder, M; Margulis, AV; Odsbu, I; Olesen, M; Perez-Gutthann, S; Phiri, K; Seeger, JD; Suehs, BT; Xu, Y | 1 |
| Du, H; Hou, J; Li, N; Xu, F | 1 |
| Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Herschorn, S; Huang, M; MacDiarmid, S; Siddiqui, E; Stoelzel, M | 1 |
| Bunniran, S; Davis, C; Kristy, R; Ng, D; Schermer, CR; Suehs, BT; Uribe, C | 1 |
| Chaudhari, S; Kish, J; Kowalski, J; Lee, W; Murray, B; Sussman, D; Yehoshua, A | 1 |
| Krivoborodov, GG; Tur, EI | 1 |
| Abrams, P; Arlandis, S; Chapple, CR; Herschorn, S; Lee, KS; Mitcheson, D; Paireddy, A; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R | 1 |
| Athanasiou, S; Cambronero Santos, J; Chapple, CR; Drake, MJ; Esen, A; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Siddiqui, E; Stoelzel, M | 1 |
| Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY | 1 |
| Almodóvar Carretón, MJ; Barreda Velázquez, C; Jamart Sánchez, L; Maestro Nombela, A; Saavedra Quirós, V | 1 |
| Fialkov, J; Herschorn, S; Schermer, CR; Staskin, D; Tu, LM; Walsh, T | 1 |
| Devlin, N; Drake, MJ; Hakimi, Z; Herdman, M; Huang, M; MacDiarmid, S; Nazir, J; Pavesi, M; Siddiqui, E | 1 |
| Brucker, BM; Chapple, CR; Drake, MJ; Fleetwood, K; Ginsberg, DA; Glanville, JM; Hepp, Z; James, D; McCool, R; Nitti, VW | 1 |
| Choo, MS; Kim, A; Shin, JH | 1 |
| Falconer, C; Hakimi, Z; Herschorn, S; Kelleher, C; Mueller, ER; Paireddy, A; Ridder, A; Robinson, D; Staskin, D; Stoelzel, M; van Maanen, R; Wang, J | 1 |
| Kato, D; Tabuchi, H; Uno, S | 2 |
| Hodgkinson, L | 1 |
| Espinosa, R; Gooch, K; Johnson, SJ; Ng, DB; Walker, D | 1 |
| Fan, A; Kato, D; Kimura, T; Uno, S; Van Schyndle, J | 1 |
| Araklitis, G; Cardozo, L | 1 |
| Kato, D; Kuroishi, K; Nozawa, Y; Tabuchi, H; Yoshida, M | 1 |
| Foley, S; Kool-Houweling, L; Nazir, J; Peters, J; Scrine, L; Wagg, AS | 1 |
| Choudhury, N; Drake, MJ; Gibson, W; Huang, M; MacDiarmid, S; Siddiqui, E; Stölzel, M | 1 |
| Geoffrion, R | 2 |
| Chapple, C; Gacci, M; Gravas, S; Kaplan, SA; McVary, KT; Moncada, I; Morgia, G; Russo, GI; Sebastianelli, A; Serni, S | 1 |
| Apostolidis, A | 1 |
| Choudhury, N; Foley, S; Freeman, R; Grill, R; Huang, M; Kachlirova, Z; Rosa Arias, J; Stari, A; Vicente, E | 1 |
| Baltogiannis, D; Dimitriadis, F; Filiponi, M; Giannakis, J; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A | 1 |
| Benedetti Panici, P; D'Oria, O; Faiano, P; Muzii, L; Schiavi, MC; Zullo, MA | 1 |
| Hanus, T; Horcicka, L; Krhut, J; Martan, A; Svabík, K; Zachoval, R; Zvara, P | 1 |
| Chen, SF; Kuo, HC | 1 |
| Matsuo, T; Miyata, Y; Nakamura, T; Sakai, H; Satoh, K | 1 |
| Baccino, D; Barra, F; Brunelli, C; Ferrero, S; Rosa, GM; Scala, C; Valbusa, A | 1 |
| Chang, HM; Chang, YC; Chen, HL; Chen, TC; Huang, WH; Juan, YS; Lee, HY; Pan, HF; Wang, YL; Wu, CM | 1 |
| Bílková, K; Borovička, V; Krhut, J; Míka, D; Mokriš, J; Sýkora, R; Zachoval, R | 1 |
| Antunes Lopes, T; Cornu, JN; Delongchamps, NB; Geavlete, B; Marcelissen, T; Rahnama'i, MS; Rashid, T; Rieken, M | 1 |
| Kuo, HC; Liao, CH | 3 |
| Azumi, M; Banjo, H; Hori, J; Kakizaki, H; Kita, M; Tamaki, G; Tsuchida, M; Wada, N; Watanabe, M | 1 |
| Fialkov, J; Gooch, K; Herschorn, S; Schermer, CR; Staskin, D; Tu, LM; Walsh, T | 1 |
| Chang, SL; Dupree, JM; Kirk, PS; Modi, PK; Singer, EA; Wang, Y | 1 |
| Elterman, D; Gomes, T; Minhas, R; Tadrous, M | 1 |
| Kuo, HC; Lee, CL | 1 |
| Aballéa, S; Chapple, C; Hakimi, Z; Kelleher, C; Maman, K; Nazir, J; Siddiqui, E; Zur, R | 1 |
| Marcelissen, TAT; Van Koeveringe, GA | 1 |
| Carlson, KV; Deal, AS; Gemmen, E; Gooch, KL; Kristy, RM; Nair, KV; Oakkar, EE; Park, J; Rovner, ES; Schermer, CR | 1 |
| Kuo, HC; Wang, CC | 1 |
| Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Paireddy, A; Rechberger, T; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ | 1 |
| Deeks, ED | 1 |
| Chuang, YC; Shen, YC; Wang, HJ | 1 |
| Gibson, W; Wagg, A | 1 |
| Kuo, HC; Lee, YK | 1 |
| Staskin, DR | 1 |
| Dimitriadis, F; Filiponi, M; Giannakis, J; Mamoulakis, C; Skouros, S; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A | 1 |
| Iatsyna, O; Kostyev, F; Vernygorodskyi, S | 1 |
| Biagioni, MC; Brucker, BM; Feigin, A; Frucht, S; Gilbert, R; Kaufmann, H; Malacarne, DR; Nitti, VW; Palma, JA; Palmerola, R; Peyronnet, B; Rosenblum, N; Sussman, RD; Vurture, G | 1 |
| Cammisotto, PG; Campeau, L; Mossa, A; Nguyen, H; Velasquez Flores, M | 1 |
| Ikeda, S; Tajima, H; Yamanishi, T; Yamanishi, Y | 1 |
| Ethans, K; Hickling, D; McKibbon, M; Radomski, S; Welk, B | 1 |
| Blázquez, AMM; Fatoye, F; González, MH; Guelfucci, F; Hakimi, Z; Khemiri, A; Nazir, J | 1 |
| Ueshima, K; Ukai, M | 1 |
| Bae, JH; Jeong, SJ; Joo, KJ; Kang, TW; Kim, HW; Kim, SW; Kim, YH; Koo, KC; Lee, YG; Shin, DG; Son, H; Song, SH; Woo, SH; Yoo, ES; Yoon, SJ | 1 |
| Gooch, KL; Johnston, KM; Khangulov, V; Rumsfeld, JS; Schermer, CR; Szabo, SM; Vonesh, E | 1 |
| Kim, JH; Lee, SR; Park, BW | 1 |
| Cui, Y; Gao, Z; Li, Y; Wang, J; Wu, J; Yuan, H; Zhou, Z; Zhu, Z | 1 |
| Seftel, AD | 1 |
| Colomer, MEB; Dolcet, MJL; Fernández-Liz, E; Martínez, AA; Rebull, JO; Tristante, PV | 1 |
| Fatoye, F; Hakimi, Z; Nazir, J; Siddiqui, E; Smith, P; Yeowell, G | 1 |
| Boer, R; Dmochowski, R; Gillard, KK; Gultyaev, D; Hessami, SH; Kaplan, S; Lister, J; Murray, B; Stanisic, S; Tung, A | 1 |
| Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 2 |
| Kitta, T | 1 |
| Arlandis-Guzmán, S; Brenes-Bermúdez, F; Duran, A; Jiménez-Cidre, MA; Mora, AM; Rubio-Rodríguez, D; Rubio-Terrés, C | 1 |
| Jiang, YH; Kuo, HC; Wang, CC | 1 |
| Korshunova, ES | 1 |
| Choo, MS; Shin, JH | 1 |
| Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Rechberger, T; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ | 1 |
| Cantaluppi, S; Coluccia, AC; Ghezzi, F; Giannantoni, A; Gubbiotti, M; Serati, M | 1 |
| Okui, N | 1 |
| Johnston, KM; Lakzadeh, P; Walker, DR | 1 |
| Griebling, TL | 5 |
| Gratzke, C; Siddiqui, E | 1 |
| Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Sassa, N; Takai, S; Yamamoto, T | 1 |
| Deighton, A; Dmochowski, R; Hawkins, N; Johnston, K; Lozano-Ortega, G; Rogula, B; Walker, D | 1 |
| Fukuhara, H; Kinjo, M; Okegawa, T; Tambo, M; Yamaguchi, T | 1 |
| Balcerzak, M; Mikkola, TS; Rahkola-Soisalo, P; Ruotsalainen, J | 1 |
| Imazumi, K; Masuda, N; Noguchi, Y; Ohtake, A; Sakamoto, K; Sato, S; Takeda, M; Ueshima, K | 1 |
| Altman, D; Elmér, C; Kopp Kallner, H | 1 |
| Schneider, MH; Struck, JP | 1 |
| Kaplan, SA | 2 |
| Almeida, FG; Bernardo, WM; Sacomani, CAR; Silvinato, A | 1 |
| Goosen, TC; Lin, J; Malhotra, B; Tse, S; Yamagami, H | 1 |
| Gao, Z; Zhou, Z | 1 |
| Hansson, F; Kilany, S; Milsom, I; Schiotz, HA; Svensson, M | 1 |
| Carlson, KV; Deal, AS; Kristy, RM; Nair, KV; Rovner, ES; Schermer, CR | 1 |
| Choudhury, N; Foley, S; Freeman, R; Huang, M; Nazir, J; Stari, A | 1 |
| Cakir, SS; Culha, MG; Degirmentepe, RB; Homma, Y; Ozbir, S | 1 |
| Amarenco, G; Chapple, CR; Everaert, K; Liehne, J; López Aramburu, MA; Lucas, M; Ridder, A; Snijder, R; Vik, V; Yamaguchi, O | 1 |
| Andersson, KE; Martin, N; Nitti, V | 1 |
| Boerrigter, P; Bosman, B; Chapple, CR; Drogendijk, T; Dvorak, V; Radziszewski, P; Ridder, A; Van Der Putten-Slob, I; Van Kerrebroeck, P; Wyndaele, JJ; Yamaguchi, O | 1 |
| Cornu, JN | 2 |
| Kashyap, M; Tyagi, P | 1 |
| Hussar, DA | 1 |
| Iwatsubo, T; Kerbusch, V; Li, Q; Miyashita, A; Nemoto, H; Takahashi, Y; Takusagawa, S; Ushigome, F; Usui, T | 1 |
| Devlin, N; Hakimi, Z; Herdman, M; Hoyle, C; Nazir, J; Odeyemi, IA; Pavesi, M | 1 |
| Andersson, KE | 2 |
| Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Herschorn, S; Khullar, V; Martin, NE; Nitti, VW; Siddiqui, E; van Kerrebroeck, P | 1 |
| Dickinson, J; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; Tretter, R; van de Wetering, J; van Gelderen, M | 1 |
| De Nunzio, C; Puccini, F; Tubaro, A | 1 |
| Barkin, J; Castro-Diaz, D; Espuna-Pons, M; Frankel, JM; Gousse, AE; Gunther, A; Herschorn, S; Martin, N; Stölzel, M; Van Kerrebroeck, P | 1 |
| Sanford, M | 1 |
| de Groat, WC | 1 |
| Andersson, KE; Hood, B; Koslov, D; Nomiya, M; Sawada, N; Zarifpour, M | 1 |
| Cui, Y; Yan, H; Yang, C; Zhang, Y; Zong, H | 1 |
| Dmochowski, R; Kaufman, M; Osborn, D; Reynolds, WS; Suarez, O | 1 |
| Caremel, R; Corcos, J; Loutochin, O | 1 |
| Lindo, FM | 1 |
| Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Khullar, V; Martin, NE; Wooning, M | 1 |
| Imran, M; Najmi, AK; Tabrez, S | 1 |
| Nakanishi, S | 1 |
| Cardozo, L; Chapple, CR; Michel, MC; Nitti, VW; Siddiqui, E | 1 |
| Amada, Y; Iitsuka, H; Katashima, M; Matsushima, H; Miyahara, H; Sawamoto, T; Takusagawa, S; Tanaka, T; Tokuno, T; van Gelderen, M | 1 |
| Aballea, S; Desroziers, K; Hakimi, Z; Maman, K; Nazir, J; Neine, ME; Odeyemi, I; Siddiqui, E | 1 |
| Siddiqui, E | 1 |
| Blauwet, MB; Chapple, CR; Herschorn, S; Khullar, V; Nitti, VW; Siddiqui, E; van Kerrebroeck, P; Wyndaele, JJ | 1 |
| Gotoh, M; Homma, Y; Igawa, Y; Ikeda, Y; Kakizaki, H; Marui, E; Nishizawa, O; Ohkawa, S; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 1 |
| Atobe, M; Hayashi, T; Kasahara, K; Kawanishi, M; Miyoshi, S; Morimoto, A; Naganuma, K; Ohashi, S; Suzuki, H | 1 |
| Bassi, P; Bientinesi, R; D'Agostino, D; Gulino, G; Racioppi, M; Sacco, E; Tienforti, D; Vittori, M | 1 |
| Challacombe, B; Dasgupta, P; Ficarra, V; Iannetti, A; Novara, G; Rossanese, M | 1 |
| Auerbach, S; Blauwet, MB; Cardozo, L; Castro-Diaz, D; Nitti, VW; Siddiqui, E; Wagg, A | 1 |
| Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R | 1 |
| Candiani, M; Cardozo, L; Cola, A; Colacurci, N; Del Deo, F; Ferrero, S; Leone Roberti Maggiore, U; Salvatore, S; Sileo, F; Torella, M | 1 |
| Auerbach, S; Blauwet, MB; Chapple, CR; Herschorn, S; Milsom, I; Nitti, VW; Radziszewski, P; Walters, C | 1 |
| De Nunzio, C; Tubaro, A | 1 |
| Kulik-Rechberger, B; Miotła, P; Rechberger, T; Wróbel, A | 1 |
| Mayr, CA; Shepherd, JP | 1 |
| Chapple, C | 1 |
| Balachandran, A; Basu, M; Curtiss, N; Duckett, J | 1 |
| Blauwet, MB; Chapple, CR; Huang, M; Kaplan, SA; Khullar, V; Mitcheson, D; Siddiqui, E | 1 |
| Blauwet, MB; Chapple, C; Frankel, J; Herschorn, S; Kaper, M; Khullar, V; Nitti, VW; Siddiqui, E | 1 |
| Ghezzi, F; Serati, M | 1 |
| Bu, SY; Cao, CX; Duan, X; Peng, CD; Wang, KJ; Wu, T | 1 |
| Kubota, Y; Kuo, HC; Kuroishi, K; Lee, KS; Na, Y; Nakaji, S; Sood, R | 1 |
| Fukuta, F; Ichihara, K; Iwasawa, A; Masumori, N; Tanaka, Y; Tsukamoto, T | 1 |
| Garnham, A; Hakimi, Z; Nazir, J; Odeyemi, IA; Posnett, J; Walker, A | 1 |
| Aballéa, S; Garnham, A; Hakimi, Z; Maman, K; Nazir, J; Odeyemi, IA; Thokagevistk, K; Toumi, M | 1 |
| Bragg, R; Hebel, D; Pitlick, JM; Vouri, SM | 1 |
| Becher, KF; Sieber, CC | 1 |
| de Groat, WC; Reese, JN; Rogers, MJ; Roppolo, JR; Schwen, Z; Shen, B; Tai, C; Wang, J; Xiao, Z | 1 |
| Blauwet, MB; Castro-Diaz, D; Chapple, CR; Delgado-Herrera, L; Hakimi, Z; Lau, W; Mujais, S | 1 |
| Funahashi, Y; Gotoh, M; Matsukawa, Y; Takai, S; Yamamoto, T | 1 |
| Boudy, AS; Thubert, T | 1 |
| Balachandran, AA; Duckett, JR | 1 |
| Hagiwara, M; Hasegawa, M; Ishioka, K; Kikuchi, E; Maeda, T; Miyajima, A; Miyazaki, Y; Oya, M; Shinojima, T | 1 |
| Iitsuka, H; Katashima, M; Sawamoto, T; Takusagawa, S; van Gelderen, M | 1 |
| Cohen, AF; Goulooze, SC; Rissmann, R | 1 |
| Abrams, P; Kay, R; Martina, R; Ridder, A; van Maanen, R | 1 |
| Cruz, F | 2 |
| Bora, GS; Mavuduru, RS; Singh, S | 1 |
| Cardozo, L; Srikrishna, S; Thiagamoorthy, G | 1 |
| Hanuš, T; Krhut, J; Martan, A; Mašata, J; Švabík, K | 1 |
| Balachandran, A; Basu, M; Duckett, J | 1 |
| Amarenco, G; Angulo, JC; Blauwet, MB; Hakimi, Z; Khullar, V; Nazir, J; Odeyemi, IA | 1 |
| Cardozo, L; Giarenis, I; Robinson, D | 1 |
| Sidaway, P | 2 |
| Karmarkar, R; Khullar, V | 1 |
| Aballéa, S; Briquet, B; Garnham, A; Hakimi, Z; Maman, K; Nazir, J; Neine, ME; Odeyemi, IA | 1 |
| de Greef-van der Sandt, I; Dorrepaal, C; Martina, R; Newgreen, D; Ridder, A; Schaddelee, M; van Maanen, R | 1 |
| Chapple, CR; Ferrero, S; Nitti, VW; Rosa, GM; Saleem, T; Wagg, A | 1 |
| Turpen, HC; Zimmern, PE | 1 |
| Pannek, J; Wöllner, J | 1 |
| Allegretti, M; Aramini, A; Benigni, F; Bettiga, A; Bianchini, G; Bovolenta, S; Brandolini, L; Castiglione, F; Colciago, G; Hedlund, P; Mistretta, FA; Montorsi, F; Russo, A; Russo, R | 1 |
| Igawa, Y; Ikeda, Y; Marui, E; Nishizawa, O; Ohkawa, S; Takeda, M; Yamaguchi, O | 1 |
| Kelleher, C; Malde, S; Nowers, J; Pindoria, N; Sahai, A; Taylor, C | 1 |
| Hanuš, T; Krhut, J; Martan, A; Švabík, K; Zachoval, R; Zvara, P | 1 |
| Balachandran, A; Duckett, J | 2 |
| Berner, T; Castro-Diaz, D; Kelleher, C; Nitti, VW; Siddiqui, E; Wagg, A | 1 |
| Blais, AS; Bolduc, S; Genois, L; Moore, K; Nadeau, G | 1 |
| Arber, M; Fleetwood, K; Freemantle, N; Ginsberg, DA; Glanville, J; Khalaf, K; Loveman, C; McCool, R; Ni, Q | 1 |
| Gravas, S; Michel, MC | 1 |
| Athanasiou, S; Cambronero, J; Chapple, C; Drake, MJ; Esen, AA; Herholdt, C; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Saleem, T; Siddiqui, E; Stölzel, M | 1 |
| Cardozo, L; Robinson, D; Thiagamoorthy, G | 1 |
| Angulo, JC; Liu, S; Luo, X; Peral, C; Ramos, J; Rejas, J; Sánchez-Ballester, F; Snedecor, SJ; Sudharshan, L | 1 |
| Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Grise, P; Hakimi, Z; Hemsted, C; Herschorn, S; Huang, M; MacDiarmid, S; Nazir, J; Saleem, T; Siddiqui, E; Stölzel, M | 1 |
| Morosetti, C; Vecchioli Scaldazza, C | 1 |
| Alcántara-Montero, A | 1 |
| Aoki, K; Fujimoto, K; Goto, D; Hirayama, A; Hosokawa, Y; Matsumoto, Y; Matsushita, C; Miyake, M; Tanaka, N; Torimoto, K; Yamada, A | 1 |
| Altman, D; Christensson, AA; Elmér, C; Flam, B; Kallner, HK | 1 |
| Campbell, NL; Klein, RW; Klein, TM; Ng, DB; Perk, S; Posta, LM; Wielage, RC; Yuran, T | 1 |
| Groen-Wijnberg, M; Kerbusch, V; Krauwinkel, W; Meijer, J; Tretter, R; van Dijk, J; van Gelderen, M; Zhang, W | 1 |
| Imamura, T; Ishizuka, O; Minagawa, T; Nagai, T; Nakazawa, M; Ogawa, T; Saito, T; Suzuki, T; Yokoyama, H | 1 |
| Asai, A; Kakoki, K; Matsuo, T; Miyata, Y; Ohba, K; Sakai, H; Yuzuriha, M | 1 |
| Abrams, P; Kay, R; Kelleher, C; Martan, A; Mincik, I; Newgreen, D; Paireddy, A; Ridder, A; Staskin, D; van Maanen, R | 1 |
| Altman, D; Andersson, KE; Elmér, C; Kallner, HK | 1 |
| Campbell, NL; Klein, RW; Klein, TM; Ng, DB; Perk, S; Perkins, A; Posta, LM; Wielage, RC; Yuran, T | 1 |
| Hashizume, K; Iuchi, H; Kakizaki, H; Kita, M; Matsumoto, S; Wada, N | 1 |
| Kato, D; Katoh, T; Kuroishi, K; Kuwamoto, K | 1 |
| Furuse, H; Kageyama, S; Kitagawa, M; Matsumoto, R; Nagae, H; Otsuka, A; Ozono, S; Suzuki, T | 1 |
| Bandari, J; Bansal, U; Chang, V; de Groat, WC; Lamm, V; Roppolo, JR; Shen, B; Tai, C; Wang, J; Zhang, Z | 1 |
| Alexandre, EC; Antunes, E; Calmasini, FB; Candido, TZ; da Silva, CPV; da Silva, FH; de Oliveira, MG; Mónica, FZ | 1 |
| Kato, D; Kuroishi, K; Nozawa, Y; Tabuchi, H | 1 |
| Kinjo, M; Nutahara, K; Sekiguchi, Y; Yoshimura, Y | 1 |
| Blais, AS; Bolduc, S; Genois, L; Moore, K; Morin, F; Nadeau, G | 1 |
| Cantaluppi, S; Finazzi Agrò, E; Ghezzi, F; Leone Roberti Maggiore, U; Serati, M; Sorice, P | 1 |
| Chapple, CR; Siddiqui, E | 1 |
| Kamai, T; Kobayashi, M; Nukui, A | 1 |
| Abbass, IM; Bradt, P; Caplan, EO; Chan, WM; Collins, JM; Kristy, R; Ng, DB; Schermer, CR; Suehs, BT | 1 |
| Hanus, T; Krhut, J; Martan, A; Masata, J; Svabik, K; Zachoval, R | 1 |
| Gur, S; Kaya, E; Oral, DY; Ozakca, I; Sikka, SC | 1 |
| Ikeda, Y; Ohkawa, S; Yamaguchi, O | 1 |
| Bowditch, S; Chapple, CR; Fatoye, F; Guelfucci, F; Hakimi, Z; Khemiri, A; Nazir, J; Siddiqui, E; Wagg, A | 1 |
| Kirby, J; Obloza, A; Toozs-Hobson, P; Yates, D | 1 |
| Legrand, F; Moyson, J; Quackels, T; Roumeguère, T; Vanden Bossche, M | 1 |
| Balykina, YE; Kolbin, AS; Proskurin, MA; Vilyum, IA | 1 |
| Hashim, H; Sharaf, A | 1 |
| Berling, M; Fatoye, F; Hakimi, Z; McCrea, C; Nazir, J; Ramos, B; Wagg, A | 1 |
| Cardozo, L; Izett, M; Robinson, D; Thiagamoorthy, G; Zacche, M | 1 |
| Tyagi, P; Tyagi, V | 1 |
| Chancellor, M; Tyagi, P; Tyagi, V | 1 |
| Gras, J | 1 |
| Bhide, AA; Digesu, GA; Fernando, R; Khullar, V | 1 |
| Sasamata, M; Seki, N; Suzuki, M; Ukai, M | 1 |
| Ellsworth, P | 1 |
| Elser, DM | 1 |
| Gillespie, JI; Guerard, M; Guilloteau, V; Korstanje, C; Lluel, P; Palea, S | 1 |
| Opar, A | 1 |
| Drogendijk, T; Eltink, C; Grunenberg, N; Iitsuka, H; Kerbusch, V; Kowalski, D; Lee, J; Matsushima, H; Meijer, J; Moy, S; Sawamoto, T; Schaddelee, M; van Gelderen, M; van Marle, S; Zhang, W | 1 |
| Andersson, KE; Hood, B | 1 |
| Auerbach, S; Calhoun, A; Herschorn, S; Lee, M; Martin, N; Nitti, VW | 1 |
| de Koning, P; Goldwater, R; Kaibara, A; Keirns, JJ; Kowalski, DL; Lee, JH; Malik, M; Moy, SS; Mujais, SK; Schaddelee, MP; van Gelderen, EM; Yen, M | 1 |
| Belavic, JM | 1 |
| Amarenco, G; Angulo, JC; Boerrigter, P; Cambronero, J; Chapple, C; Drogendijk, T; Høye, K; Khullar, V; Milsom, I; Radziszewski, P; Rechberger, T; Wooning, M | 1 |
| Chapple, CR; Cummings, J; Dorrepaal, C; Drogendijk, T; Kaplan, SA; Klecka, J; Martin, N; Mitcheson, D | 1 |
| Cornu, JN; Novara, G | 1 |
| Kosaka, T; Kuwahara, Y; Mishima, J; Nakamura, K; Otsuki, H; Tsukamoto, T | 1 |
| Hussar, DA; Martinez, LN | 1 |
| Hatanaka, T; Ohtake, A; Sasamata, M; Sato, S; Someya, A; Suzuki, M; Ueshima, K; Ukai, M; Watanabe, M | 1 |
| Andersson, KE; Bouchelouche, K; Bouchelouche, P; Korstanje, C; Nordling, J; Svalø, J | 1 |
| Muller, N | 1 |
| Lazzeri, M | 1 |
75 review(s) available for thiazoles and Bladder, Overactive
| Article | Year |
|---|---|
Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Muscarinic Antagonists; Pyrimidinones; Pyrrolidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cholinergic Antagonists; Constipation; Female; Humans; Hypertension; Male; Middle Aged; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Safety; Tachycardia; Thiazoles; Urinary Bladder, Overactive; Urinary Tract Infections; Vision, Low; Xerostomia | 2021 |
Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review.
Topics: Acetanilides; Adult; Cholinergic Antagonists; Humans; Multiple Sclerosis; Randomized Controlled Trials as Topic; Retrospective Studies; Spinal Cord Injuries; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics | 2022 |
Effectiveness and tolerability of mirabegron in children with overactive bladder: A retrospective pilot study.
Topics: Acetanilides; Adolescent; Child; Female; Humans; Male; Pilot Projects; Retrospective Studies; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2020 |
The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
What affects the placebo effect?
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Data Collection; Humans; Patient Reported Outcome Measures; Placebo Effect; Thiazoles; Urinary Bladder, Overactive | 2020 |
Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Delayed-Action Preparations; Humans; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2020 |
Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.
Topics: Acetanilides; Age Factors; Aged; Aged, 80 and over; Female; Humans; Lower Urinary Tract Symptoms; Nocturia; Patient Safety; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2020 |
Effect of Mirabegron on the Body's Exercise Capacity: A Review.
Topics: Acetanilides; Adipose Tissue; Adipose Tissue, Brown; Adipose Tissue, White; Adrenergic beta-3 Receptor Agonists; Animals; Exercise Tolerance; Humans; Lipolysis; Thiazoles; Urinary Bladder, Overactive | 2020 |
Mirabegron in female patients with overactive bladder syndrome: What's new? A systematic review and meta-analysis.
Topics: Acetanilides; Female; Humans; Male; Muscarinic Antagonists; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder.
Topics: Acetanilides; Aged; Behavior Therapy; Benzilates; Blood-Brain Barrier; Cholinergic Antagonists; Cognitive Dysfunction; Female; Humans; Muscarinic Antagonists; Nortropanes; Thiazoles; Urinary Bladder, Overactive | 2020 |
Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.
Topics: Acetanilides; Aged; Benzhydryl Compounds; Constipation; Female; Humans; Male; Muscarinic Antagonists; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Recent advances in managing overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Botulinum Toxins; Denervation; Drug Implants; Humans; Laser Therapy; Pyrimidinones; Pyrrolidines; Tamoxifen; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Evaluating vibegron for the treatment of overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Pyrimidinones; Pyrrolidines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Cholinergic Antagonists; Cost-Benefit Analysis; Humans; Muscarinic Antagonists; Phosphodiesterase Inhibitors; Pyrimidinones; Pyrrolidines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Mirabegron: Pediatric First Approval.
Topics: Acetanilides; Administration, Oral; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Male; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis.
Topics: Acetanilides; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
[Comprehensive pharmacologic management of overactive bladder].
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Combinations; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Sulfonamides; Tamsulosin; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive | 2017 |
[Mirabegron, a breakthrough in overactive bladder syndrome?]
Topics: Acetanilides; Humans; Quality of Life; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2017 |
Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.
Topics: Acetanilides; Administration, Oral; Botulinum Toxins, Type A; Cholinergic Antagonists; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2017 |
Safety issues associated with using medication to treat overactive bladder.
Topics: Acetanilides; Aged; Botulinum Toxins; Cholinergic Antagonists; Estrogens; Humans; Polypharmacy; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2017 |
Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
Topics: Acetanilides; Humans; Lower Urinary Tract Symptoms; Nocturia; Randomized Controlled Trials as Topic; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Cardiovascular Diseases; Heart Rate; Humans; Hypertension; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2018 |
Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents | 2018 |
Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?
Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Aged; Case-Control Studies; Cholinergic Antagonists; Drug Therapy, Combination; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Compliance; Prevalence; Quality of Life; Thiazoles; Urinary Bladder, Overactive | 2019 |
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Recovery of Function; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2018 |
Mirabegron: A Review in Overactive Bladder Syndrome.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Muscarinic Antagonists; Signal Transduction; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2018 |
Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
Topics: Acetanilides; Humans; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2019 |
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Medication Adherence; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2018 |
[Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder.]
Topics: Acetanilides; Cost-Benefit Analysis; Humans; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2018 |
[New approach to the treatment of patients with overactive bladder. Mirabegron: past, present and future].
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Russia; Thiazoles; Urinary Bladder, Overactive | 2018 |
Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review.
Topics: Acetanilides; Botulinum Toxins, Type A; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Reported Outcome Measures; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis.
Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Antagonists; Aged; Aged, 80 and over; Bayes Theorem; Botulinum Toxins, Type A; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Muscarinic Antagonists; Network Meta-Analysis; Prognosis; Randomized Controlled Trials as Topic; Retreatment; Thiazoles; Treatment Failure; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2019 |
Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Thiazoles; Urinary Bladder, Overactive | 2013 |
Actual treatment of overactive bladder and urge urinary incontinence.
Topics: Acetanilides; Botulinum Toxins, Type A; Caffeine; Clinical Trials, Phase III as Topic; Drinking Behavior; Electric Stimulation Therapy; Electrodes, Implanted; Exercise Therapy; Female; Humans; Male; Multicenter Studies as Topic; Muscarinic Antagonists; Neurokinin-1 Receptor Antagonists; Pelvic Floor Disorders; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Therapies, Investigational; Thiazoles; Urinary Bladder Neck Obstruction; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urologic Surgical Procedures | 2013 |
The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.
Topics: Acetanilides; Biological Availability; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Europe; Humans; Japan; Kidney; Liver; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Thiazoles; United States; Urinary Bladder, Overactive | 2013 |
β3-receptor agonists for overactive bladder--new frontier or more of the same?
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Practice Guidelines as Topic; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urination | 2013 |
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phenylpropanolamine; Randomized Controlled Trials as Topic; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult | 2013 |
Mirabegron: a review of its use in patients with overactive bladder syndrome.
Topics: Acetanilides; Humans; Randomized Controlled Trials as Topic; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2013 |
The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials.
Topics: Acetanilides; Clinical Trials, Phase III as Topic; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urination | 2014 |
What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Dose-Response Relationship, Drug; Female; Humans; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2013 |
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2014 |
Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
Topics: Acetanilides; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2014 |
Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2014 |
Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urinary Tract; Urological Agents | 2014 |
Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2015 |
The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Age Factors; Aged; Clinical Trials, Phase III as Topic; Humans; Randomized Controlled Trials as Topic; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2014 |
Mirabegron in the treatment of overactive bladder.
Topics: Acetanilides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2014 |
[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
Topics: Acetanilides; Adrenergic beta-3 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence | 2014 |
Cost-effectiveness of novel therapies for overactive bladder.
Topics: Acetanilides; Adult; Behavior Therapy; Botulinum Toxins, Type A; Cost-Benefit Analysis; Electric Stimulation Therapy; Humans; Muscarinic Antagonists; Thiazoles; Tibial Nerve; Urinary Bladder, Overactive | 2014 |
The role of mirabegron in overactive bladder: a systematic review and meta-analysis.
Topics: Acetanilides; Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Odds Ratio; Phenylpropanolamine; Prospective Studies; Research Design; Software; Surveys and Questionnaires; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2014 |
The use of pharmacotherapy for male patients with urgency and stress incontinence.
Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urinary Incontinence, Urge; Urological Agents | 2014 |
Mirabegron: a Beta-3 agonist for overactive bladder.
Topics: Acetanilides; Humans; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2014 |
[Urinary incontinence: what's new in therapy?].
Topics: Acetanilides; Administration, Intravesical; Aged; Behavior Therapy; Botulinum Toxins, Type A; Cholinergic Antagonists; Combined Modality Therapy; Cooperative Behavior; Female; Humans; Interdisciplinary Communication; Male; Thiazoles; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence | 2015 |
Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2015 |
Emerging drugs for overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Botulinum Toxins, Type A; Drug Design; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Quality of Life; Thiazoles; Urinary Bladder, Overactive | 2015 |
Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aniline Compounds; Benzoates; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Heart Rate; Humans; Thiazoles; Urinary Bladder, Overactive | 2016 |
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Topics: Acetanilides; Administration, Oral; Adrenergic beta-Antagonists; Aged; Benzhydryl Compounds; Blood Pressure; Clinical Trials as Topic; Constipation; Female; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Retrospective Studies; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2016 |
Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.
Topics: Acetanilides; Botulinum Toxins, Type A; Humans; Nocturia; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2016 |
Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aniline Compounds; Animals; Benzoates; Biphenyl Compounds; Gene Expression Profiling; Humans; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive | 2016 |
A drug safety evaluation of mirabegron in the management of overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2016 |
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
Topics: Acetanilides; Aged; Asia; Humans; Male; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2017 |
β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Lower Urinary Tract Symptoms; Male; Male Urogenital Diseases; Muscarinic Antagonists; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive | 2018 |
[Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].
Topics: Acetanilides; Botulinum Toxins, Type A; Cholinergic Antagonists; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2017 |
Profile of mirabegron in the treatment of overactive bladder: place in therapy.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Thiazoles; Urinary Bladder, Overactive | 2017 |
Current evidence and emerging drug therapies for overactive bladder.
Topics: Acetanilides; Drug Design; Humans; Muscarinic Antagonists; Quality of Life; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2017 |
Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Rats; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urination Disorders | 2010 |
Mirabegron: a safety review.
Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials, Phase II as Topic; Drug Interactions; Humans; Thiazoles; Urinary Bladder, Overactive | 2011 |
Use of mirabegron in treating overactive bladder.
Topics: Acetanilides; Adrenergic beta-Agonists; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
[Pharmacological and clinical profile of mirabegron (Betanis(®)): a new therapeutic agent for overactive bladder].
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials, Phase III as Topic; Humans; Muscle Relaxation; Muscle, Smooth; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive | 2012 |
Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aniline Compounds; Behavior Therapy; Benzoates; Biphenyl Compounds; Botulinum Toxins, Type A; Clinical Trials as Topic; Electric Stimulation Therapy; Humans; Muscarinic Antagonists; Neuromuscular Agents; Sacrum; Thiazoles; Tibial Nerve; Urinary Bladder, Overactive | 2012 |
Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management.
Topics: Acetanilides; Behavior Therapy; Botulinum Toxins, Type A; Catheter Ablation; Catheterization; Electric Stimulation Therapy; Exercise Therapy; Female; Humans; Neuromuscular Agents; Physical Therapy Modalities; Stem Cell Transplantation; Suburethral Slings; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urologic Surgical Procedures | 2012 |
Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.
Topics: Acetanilides; Afferent Pathways; Animals; Botulinum Toxins, Type A; Carbolines; Humans; Phosphodiesterase 5 Inhibitors; Tadalafil; Thiazoles; Urinary Bladder, Overactive | 2013 |
87 trial(s) available for thiazoles and Bladder, Overactive
| Article | Year |
|---|---|
Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study.
Topics: Acetanilides; Adult; Benzofurans; Humans; Prospective Studies; Pyrrolidines; Stroke; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors.
Topics: Acetanilides; Aged; BCG Vaccine; Cystectomy; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Thiazoles; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urological Agents | 2021 |
Efficacy of mirabegron, a β
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Double-Blind Method; Female; Humans; Japan; Muscarinic Antagonists; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2022 |
The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial.
Topics: Acetanilides; Double-Blind Method; Humans; Parkinson Disease; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2022 |
Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study.
Topics: Acetanilides; Aged; Aged, 80 and over; Central Nervous System Diseases; Cognition; Cohort Studies; Drug Therapy, Combination; Humans; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2022 |
Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial.
Topics: Acetanilides; Female; Humans; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Vascular Stiffness | 2022 |
Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.
Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Prospective Studies; Pyrimidinones; Pyrrolidines; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2023 |
Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
Topics: Acetanilides; Aged; Aged, 80 and over; Benzilates; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Databases, Factual; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Humans; Middle Aged; Prospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Visual Analog Scale | 2019 |
Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Single-Blind Method; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Female; Humans; Male; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin/solifenacin combination: A randomized controlled trial.
Topics: Acetanilides; Adult; Drug Therapy, Combination; Humans; Middle Aged; Quality of Life; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Catheters; Urological Agents | 2020 |
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.
Topics: Acetanilides; Adipose Tissue, Brown; Adolescent; Adult; Apolipoprotein A-I; Biomarkers; Cholesterol, HDL; Female; Humans; Insulin Resistance; Positron Emission Tomography Computed Tomography; Thiazoles; Urinary Bladder, Overactive | 2020 |
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Topics: Acetanilides; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2020 |
Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR).
Topics: Acetanilides; Aged; Cognition; Female; Humans; Male; Mental Status and Dementia Tests; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Age Factors; Aged; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Severity of Illness Index; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2020 |
Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study.
Topics: Acetanilides; Adult; Constipation; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Patient Reported Outcome Measures; Prospective Studies; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
Topics: Acetanilides; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Single-Blind Method; Solifenacin Succinate; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study.
Topics: Acetanilides; Age Factors; Aged; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Tamsulosin; Thiazoles; Urinary Bladder, Overactive | 2021 |
Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Urinary Bladder, Overactive | 2021 |
Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study.
Topics: Acetanilides; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Quality of Life; Single-Blind Method; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
Topics: Acetanilides; Aged; Double-Blind Method; Female; Humans; Male; Parkinson Disease; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Prospective Studies; Spinal Cord Injuries; Thiazoles; Urinary Bladder, Overactive; Young Adult | 2021 |
Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non-neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)-An open label randomised controlled clinical stud
Topics: Acetanilides; Drug Therapy, Combination; Humans; Male; Prostatic Hyperplasia; Quality of Life; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder.
Topics: Acetanilides; Botulinum Toxins, Type A; Humans; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Age Factors; Child; Child, Preschool; Egypt; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2021 |
Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial.
Topics: Acetanilides; Double-Blind Method; Female; Humans; Mandelic Acids; Nocturia; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Topics: Acetanilides; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Internationality; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Risk Assessment; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2017 |
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2017 |
Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.
Topics: Acetanilides; Adult; Female; Humans; Middle Aged; Prospective Studies; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination; Urine; Urodynamics; Urological Agents | 2018 |
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
Topics: Acetanilides; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Preference; Prospective Studies; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2017 |
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Topics: Acetanilides; Double-Blind Method; Drug Therapy, Combination; Humans; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Visual Analog Scale | 2018 |
Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Male; Product Surveillance, Postmarketing; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Topics: Acetanilides; Aged; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2017 |
Is it possible to cure the symptoms of the overactive bladder in women?
Topics: Acetanilides; Aged; Feasibility Studies; Female; Humans; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Recurrence; Severity of Illness Index; Symptom Assessment; Thiazoles; Time Factors; Urinary Bladder, Overactive; Urological Agents; Withholding Treatment | 2018 |
Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study.
Topics: Acetanilides; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents; Young Adult | 2018 |
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Topics: Acetanilides; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Quality of Life; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents | 2018 |
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Topics: Acetanilides; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Symptom Assessment; Thiazoles; Time; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2018 |
The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Female; Humans; Middle Aged; Orgasm; Prospective Studies; Sexual Health; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.
Topics: Acetanilides; Adult; Aged; Canada; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pilot Projects; Spinal Cord Injuries; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2018 |
Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder.
Topics: Acetanilides; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Taiwan; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2019 |
Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
Topics: Acetanilides; Aged; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents | 2019 |
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Benzilates; Blood Pressure; Constipation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Nasopharyngitis; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Xerostomia | 2019 |
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult | 2019 |
Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
Topics: Acetanilides; Aged; Aged, 80 and over; Benzhydryl Compounds; Drug Therapy, Combination; Humans; Indoles; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2019 |
A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Nocturia; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents | 2013 |
A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Incidence; Internationality; Male; Middle Aged; Quality of Life; Single-Blind Method; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2013 |
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Metoprolol; Middle Aged; Thiazoles; Urinary Bladder, Overactive; Young Adult | 2014 |
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Female; Headache; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tachycardia; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2013 |
Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
Topics: Acetanilides; Aged; Aged, 80 and over; Australia; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prevalence; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2013 |
Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
Topics: Acetanilides; Adrenergic Agonists; Adult; Asian People; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Japan; Male; Single-Blind Method; Thiazoles; Urinary Bladder, Overactive; Young Adult | 2014 |
Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Asian People; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2014 |
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Double-Blind Method; Drug Combinations; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents | 2015 |
Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Off-Label Use; Placebos; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2014 |
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Headache; Humans; Hypertension; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Retention; Urinary Tract Infections; Urination; Xerostomia | 2014 |
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2015 |
Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Asia; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Recovery of Function; Surveys and Questionnaires; Thiazoles; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents | 2015 |
A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Thiazoles; Urinary Bladder, Overactive | 2015 |
Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
Topics: Acetanilides; Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Double-Blind Method; Humans; Phenylpropanolamine; Quality of Life; Thiazoles; Tolterodine Tartrate; United Kingdom; Urinary Bladder, Overactive; Urological Agents | 2015 |
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2015 |
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.
Topics: Acetanilides; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2015 |
Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.
Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Prospective Studies; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents | 2015 |
Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.
Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Asian People; Eating; Fasting; Female; Healthy Volunteers; Humans; Male; Sex Factors; Thiazoles; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2015 |
A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OAB.
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2016 |
Patient-reported outcomes with the β
Topics: Absenteeism; Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Female; Humans; Incontinence Pads; Male; Middle Aged; Muscarinic Antagonists; Patient Reported Outcome Measures; Quality of Life; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Decision Support Techniques; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Risk Assessment; Risk Factors; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2015 |
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2016 |
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics; Young Adult | 2016 |
Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2016 |
Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Double-Blind Method; Drug Therapy, Combination; Humans; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2016 |
Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Cross-Over Studies; Female; Humans; Imidazoles; Middle Aged; Muscarinic Antagonists; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2017 |
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYM
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Patient Reported Outcome Measures; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2017 |
Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Cardiovascular Diseases; Female; Humans; Male; Marketing; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2016 |
Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).
Topics: Acetanilides; Double-Blind Method; Female; Humans; Imidazoles; Muscarinic Antagonists; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
Topics: Acetanilides; Drug Substitution; Female; Humans; Long-Term Care; Postmenopause; Prospective Studies; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Young Adult | 2017 |
Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Topics: Acetanilides; Administration, Oral; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Biological Availability; Biotransformation; Body Weight; Cross-Over Studies; Female; Humans; Infusions, Intravenous; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Netherlands; Sex Factors; Thiazoles; Urinary Bladder, Overactive; Washington; Young Adult | 2012 |
Results of a randomized phase III trial of mirabegron in patients with overactive bladder.
Topics: Acetanilides; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive | 2013 |
Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Topics: Acetanilides; Adolescent; Adrenergic beta-Agonists; Adult; Anti-Infective Agents; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Quinolines; Sex Characteristics; Thiazoles; Urinary Bladder, Overactive; Young Adult | 2012 |
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Australia; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Europe; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Single-Blind Method; Surveys and Questionnaires; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination | 2013 |
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Benzhydryl Compounds; Constipation; Cresols; Delayed-Action Preparations; Double-Blind Method; Female; Headache; Humans; Hypertension; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Single-Blind Method; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urinary Retention; Xerostomia | 2013 |
β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Thiazoles; Ultrasonography; Urinary Bladder, Overactive; Urodynamics | 2013 |
194 other study(ies) available for thiazoles and Bladder, Overactive
| Article | Year |
|---|---|
Mirabegron has longer treatment persistence than antimuscarinics: Real-world data from a Korean national cohort database.
Topics: Acetanilides; Adult; Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
The effect of Mirabegron and Duloxetine combination in mixed-type urinary incontinence treatment.
Topics: Acetanilides; Double-Blind Method; Duloxetine Hydrochloride; Humans; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2021 |
Editorial Comment to Efficacy of mirabegron, a β
Topics: Acetanilides; Double-Blind Method; Female; Humans; Japan; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence | 2022 |
Transcutaneous electrical nerve stimulation as add-on therapy in children receiving anticholinergics and/or mirabegron for refractory daytime urinary incontinence: A retrospective cohort study.
Topics: Acetanilides; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Diurnal Enuresis; Humans; Retrospective Studies; Thiazoles; Transcutaneous Electric Nerve Stimulation; Treatment Outcome; Urinary Bladder, Overactive | 2022 |
Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study.
Topics: Acetanilides; Child; Humans; Pilot Projects; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2022 |
Inhibition of Full Smooth Muscle Contraction in Isolated Human Detrusor Tissues by Mirabegron Is Limited to Off-Target Inhibition of Neurogenic Contractions.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetanilides; Carbachol; Endothelin-1; Female; Humans; Male; Methacholine Chloride; Muscle Contraction; Muscle, Smooth; Receptors, Adrenergic; Thiazoles; Urinary Bladder, Overactive | 2022 |
Overactive bladder medication: Anticholinergics versus mirabegron by specialty.
Topics: Acetanilides; Aged; Cholinergic Antagonists; Humans; Medicare; Thiazoles; Treatment Outcome; United States; Urinary Bladder, Overactive; Urological Agents | 2022 |
Resource use and healthcare costs in patients with overactive bladder who initiate treatment with mirabegron or antimuscarinic monotherapy in Catalonia: the MIRACAT study.
Topics: Acetanilides; Adult; Female; Health Care Costs; Humans; Male; Muscarinic Antagonists; Quality of Life; Retrospective Studies; Spain; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2022 |
Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged, 80 and over; Female; Frail Elderly; Humans; Japan; Male; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2022 |
Re: Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study.
Topics: Acetanilides; Child; Female; Humans; Male; Pilot Projects; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive | 2022 |
Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women.
Topics: Acetanilides; Adult; Aged; Female; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2022 |
Continuous administration of mirabegron has advantages in inhibition of central sensitization compared with short-term treatment cessation in a mouse model of overactive bladder.
Topics: Acetanilides; Animals; Central Nervous System Sensitization; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thiazoles; Urinary Bladder, Overactive | 2022 |
Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder.
Topics: Acetanilides; Aged; Blood Pressure; Heart Rate; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2022 |
Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice.
Topics: Acetanilides; Animals; Carbachol; Female; Mice; Muscarinic Antagonists; Solifenacin Succinate; Stress, Psychological; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2022 |
Vibegron for the treatment of overactive bladder: a comprehensive update.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Pyrimidinones; Pyrrolidines; Receptors, Adrenergic, beta-3; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2022 |
Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms.
Topics: Acetanilides; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Penile Erection; Prospective Studies; Thiazoles; Urinary Bladder, Overactive | 2020 |
Treatment of Elderly Patients with Overactive Bladder: Has Mirabegron Come of Age?
Topics: Acetanilides; Aged; Double-Blind Method; Humans; Thiazoles; Urinary Bladder, Overactive | 2020 |
Effects of combined treatment with fesoterodine and mirabegron in a pelvic congestion rat model: Results from in vitro and in vivo functional studies.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Benzhydryl Compounds; Cresols; Disease Models, Animal; Drug Monitoring; Drug Therapy, Combination; Female; Muscarinic Antagonists; Rats; Rats, Sprague-Dawley; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Cohort Studies; Female; Humans; Male; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive | 2020 |
Re: Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE.
Topics: Acetanilides; Aged; Europe; Humans; Quality of Life; Thiazoles; Urinary Bladder, Overactive | 2020 |
Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways.
Topics: Acetanilides; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Duloxetine Hydrochloride; Female; Locomotion; Rats; Rats, Wistar; Signal Transduction; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Exploratory analysis of the effect of mirabegron on urodynamic sensation parameters and urethral pressure variations.
Topics: Acetanilides; Adult; Female; Humans; Prospective Studies; Sensation; Thiazoles; Urinary Bladder, Overactive; Urodynamics | 2021 |
Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis.
Topics: Acetanilides; Animals; Cyclophosphamide; Cystitis; Disease Models, Animal; Drug Therapy, Combination; Male; Nitric Oxide; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Female; Humans; Italy; Medication Adherence; Middle Aged; Prospective Studies; Thiazoles; Urinary Bladder, Overactive | 2020 |
Quality of life and treatment persistence evaluation in Spanish patients treated with mirabegron. Results of the BELIEVE study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Male; Middle Aged; Quality of Life; Retrospective Studies; Self Report; Spain; Thiazoles; Urinary Bladder, Overactive | 2020 |
Editorial Comment.
Topics: Acetanilides; Humans; Male; Prostatic Hyperplasia; Tamsulosin; Thiazoles; Urinary Bladder, Overactive | 2020 |
The Efficacy of Mirabegron for the Relief of Ureteral Stent-Related Symptoms.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Lithotripsy; Male; Middle Aged; Prospective Studies; Quality of Life; Stents; Thiazoles; Urinary Bladder, Overactive; Urinary Calculi | 2020 |
Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.
Topics: Acetanilides; Aged; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
FDG Uptake in Brown Adipose Tissue Activated by a β3-Adrenergic Receptor Agonist Prescribed for Overactive Bladder.
Topics: Acetanilides; Adipose Tissue, Brown; Adrenal Gland Neoplasms; Adrenergic Agonists; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Pheochromocytoma; Positron-Emission Tomography; Radiopharmaceuticals; Thiazoles; Urinary Bladder, Overactive | 2020 |
[Analysis of costs and consequences related to the persistence of Mirabegron and antimuscarinic treatments and their impact on quality of life in patients with overactive bladder in Spain: Results of a probabilistic model.]
Topics: Acetanilides; Humans; Models, Statistical; Muscarinic Antagonists; Quality of Life; Spain; Thiazoles; Urinary Bladder, Overactive | 2020 |
Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study.
Topics: Acetanilides; Adrenergic alpha-Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2020 |
Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
Topics: Acetanilides; Aged; Female; Humans; Male; Prostatic Hyperplasia; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2021 |
Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction.
Topics: Acetanilides; Adolescent; Child; Humans; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics | 2020 |
Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
Topics: Acetanilides; Adult; Aged; Botulinum Toxins, Type A; Combined Modality Therapy; Electric Stimulation Therapy; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Thiazoles; Tibial Nerve; United States; Urinary Bladder, Overactive | 2020 |
A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
Topics: Acetanilides; Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Prospective Studies; Retreatment; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2020 |
Overactive bladder medication: Persistence, drug switching, and reinitiation.
Topics: Acetanilides; Adult; Aged; Drug Substitution; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Re: Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Topics: Acetanilides; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2020 |
"First, Do No Harm"-Trainees' Observation of Risk Reduction in the Treatment of Overactive Bladder.
Topics: Acetanilides; Aged; Cholinergic Antagonists; Dementia; Female; Humans; Insurance Coverage; Middle Aged; Risk; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2021 |
Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: A prospective study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Female; Humans; Male; Prospective Studies; Spinal Cord Injuries; Thiazoles; Urinary Bladder, Overactive | 2021 |
Development and Optimization of Mirabegron Solid Lipid Nanoparticles as an Oral Drug Delivery for Overactive Bladder.
Topics: Acetanilides; Animals; Drug Delivery Systems; Lipids; Nanoparticles; Pharmaceutical Preparations; Rats; Rats, Wistar; Thiazoles; Urinary Bladder, Overactive | 2021 |
Comment on "A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study)".
Topics: Acetanilides; Humans; Muscarinic Antagonists; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Thiazoles; Urinary Bladder, Overactive | 2021 |
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Topics: Acetanilides; Female; Humans; Male; Muscarinic Antagonists; Neoplasms; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Animals; Brain; Male; Muscarinic Antagonists; Muscle Contraction; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Submandibular Gland; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents | 2021 |
Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Calcium Signaling; Cyclic AMP; Disease Models, Animal; Drug Therapy, Combination; Female; HEK293 Cells; Humans; Muscarinic Antagonists; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-3; Thiazoles; Tolterodine Tartrate; TRPM Cation Channels; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2021 |
Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
Topics: Acetanilides; Adolescent; Age Factors; Child; Child, Preschool; Female; Humans; Male; Retrospective Studies; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study.
Topics: Acetanilides; Adult; Humans; Muscarinic Antagonists; Prospective Studies; Registries; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study.
Topics: Acetanilides; Adolescent; Adult; Child; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urodynamics | 2021 |
The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy.
Topics: Acetanilides; Aged; Aged, 80 and over; Cholinergic Antagonists; Cognition; Humans; Pilot Projects; Spinal Cord Injuries; Thiazoles; Urinary Bladder, Overactive | 2021 |
Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study.
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pilot Projects; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2022 |
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Topics: Acetanilides; Aged; Cardiovascular Diseases; Cohort Studies; Female; Heart Disease Risk Factors; Humans; Male; Muscarinic Antagonists; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2021 |
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Catheterization; Cohort Studies; Female; Humans; Incidence; Male; Middle Aged; Muscarinic Antagonists; Prostatic Diseases; Randomized Controlled Trials as Topic; Residual Volume; Risk; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Retention; Urodynamics; Urological Agents | 2017 |
A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Male; Muscarinic Antagonists; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
Topics: Acetanilides; Adult; Aged; Cholinergic Antagonists; Databases, Factual; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Patient Compliance; Retrospective Studies; Thiazoles; Treatment Refusal; Urinary Bladder, Overactive; Urological Agents | 2017 |
Better Persistence Rates with Mirabegron: Questions Raised.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Thiazoles; Urinary Bladder, Overactive | 2017 |
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2017 |
Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Long-Term Care; Male; Middle Aged; Product Surveillance, Postmarketing; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2019 |
American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA).
Topics: Acetanilides; Administration, Intranasal; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials, Phase III as Topic; Deamino Arginine Vasopressin; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Hydrogels; Mitomycin; Multicenter Studies as Topic; Nocturia; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; United States; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urology | 2017 |
The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Topics: Acetanilides; Adult; Aged; Botulinum Toxins, Type A; Female; Health Expenditures; Health Resources; Humans; Insurance Claim Review; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents | 2017 |
Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.
Topics: Acetanilides; Adult; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Thiazoles; Urinary Bladder, Overactive | 2017 |
Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Cohort Studies; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Thiazoles; United Kingdom; Urinary Bladder, Overactive | 2017 |
No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.
Topics: Acetanilides; Benzhydryl Compounds; Drug Therapy, Combination; Female; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2017 |
N
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Benzhydryl Compounds; Contraindications, Drug; Drug Therapy, Combination; Female; Humans; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2017 |
Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?
Topics: Acetanilides; Cholinergic Antagonists; Drug Therapy, Combination; Follow-Up Studies; Humans; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2017 |
Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.
Topics: Acetanilides; Aged; Female; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive | 2018 |
Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Antidiuretic Agents; Deamino Arginine Vasopressin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscarinic Antagonists; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2017 |
Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
Topics: Acetanilides; Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Retrospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2018 |
Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
Topics: Acetanilides; Aged; Central Nervous System Diseases; Dementia; Female; Humans; Male; Parkinson Disease; Stroke; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.
Topics: Acetanilides; Aged; Aged, 80 and over; Female; Human T-lymphotropic virus 1; Humans; Middle Aged; Paraparesis, Tropical Spastic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Quality of Life; Severity of Illness Index; Thiazoles; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2018 |
Long-term persistence with mirabegron in a real-world clinical setting.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Proportional Hazards Models; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2018 |
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications.
Topics: Acetanilides; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Databases as Topic; Drug Industry; Drug Prescriptions; Humans; Indoles; Medicare Part D; Practice Patterns, Physicians'; Solifenacin Succinate; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents; Urology | 2018 |
Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Benzhydryl Compounds; Canada; Cholinergic Antagonists; Cross-Sectional Studies; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Efficacy and safety of mirabegron, a β
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Female; Humans; Male; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2019 |
Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?
Topics: Acetanilides; Humans; Muscarinic Antagonists; Network Meta-Analysis; Thiazoles; Urinary Bladder, Overactive | 2018 |
A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
Topics: Acetanilides; Female; Follow-Up Studies; Humans; Male; Muscarinic Antagonists; Prospective Studies; Registries; Research Design; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Prospective Studies; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2019 |
Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice.
Topics: Acetanilides; Adult; Aged; Female; Humans; Hypertension; Male; Middle Aged; Patient Dropouts; Quality of Life; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2018 |
Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
Topics: Acetanilides; Benzhydryl Compounds; Canada; Humans; Thiazoles; Urinary Bladder, Overactive | 2018 |
Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities.
Topics: Acetanilides; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multimorbidity; Patient Safety; Prospective Studies; Quality of Life; Risk Assessment; Sex Factors; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Combination Therapy for Overactive Bladder: Who Approves?
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2018 |
MORPHOLOGICAL ASSESSMENT OF NO-SYNTHASE DISTRIBUTION IN OVERACTIVE BLADDER AND STRESS URINE INCONTINENCE IN ANIMAL MODELS ADMINISTERED WITH EXPERIMENTAL PHARMACOCORRECTION REGIMENS.
Topics: Acetanilides; Animals; Benzilates; Drug Therapy, Combination; Estradiol; Female; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nortropanes; Quercetin; Rats; Testosterone; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence, Stress | 2018 |
Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort.
Topics: Acetanilides; Aged; Cohort Studies; Female; Humans; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
Topics: Acetanilides; Aged; Female; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2019 |
Beta-3 Adrenoceptor Signaling Pathways in Urothelial and Smooth Muscle Cells in the Presence of Succinate.
Topics: Acetanilides; Animals; Cyclic AMP; Female; Metabolic Syndrome; Muscle Relaxation; Muscle, Smooth; Myocytes, Smooth Muscle; Nitric Oxide; Nitric Oxide Synthase Type II; Rats; Receptors, Adrenergic, beta-3; Signal Transduction; Succinic Acid; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urothelium | 2018 |
Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?
Topics: Acetanilides; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Humans; Japan; Markov Chains; Muscarinic Antagonists; Quality of Life; Severity of Illness Index; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2018 |
A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Topics: Acetanilides; Aged; Aged, 80 and over; Female; Humans; Linear Models; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Proportional Hazards Models; Retrospective Studies; Spain; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2018 |
[Contribution of pharmacological research to the discovery of a first-in-class drug, mirabegron, for the treatment of overactive bladder].
Topics: Acetanilides; Animals; Humans; Rats; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2018 |
Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
Topics: Acetanilides; Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Data Interpretation, Statistical; Databases, Factual; Electronic Health Records; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Propensity Score; Retrospective Studies; Risk Factors; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2018 |
Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eu
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2019 |
Re: The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study.
Topics: Acetanilides; Female; Humans; Prospective Studies; Thiazoles; Urinary Bladder, Overactive | 2018 |
Re: Efficacy and Safety of Combinations of Mirabegron and Solifenacin Compared with Monotherapy and Placebo in Patients with Overactive Bladder (SYNERGY Study).
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2018 |
Effectiveness of an intervention to optimise the use of mirabegron for overactive bladder: a quasi-experimental study in primary care.
Topics: Acetanilides; Aged; Aged, 80 and over; Controlled Before-After Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Primary Health Care; Spain; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Cost-effectiveness of overactive bladder treatments: from the US payer perspective.
Topics: Acetanilides; Botulinum Toxins, Type A; Cholinergic Antagonists; Cost-Benefit Analysis; Electric Stimulation Therapy; Electrodes, Implanted; Health Care Costs; Humans; Middle Aged; Neuromuscular Agents; Thiazoles; Treatment Outcome; United States; Urinary Bladder, Overactive; Urological Agents | 2019 |
Editorial Comment to Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Topics: Acetanilides; Humans; Japan; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2019 |
Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB.
Topics: Acetanilides; Aged; Female; Humans; Male; Quality of Life; Recurrence; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2019 |
Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Drug Substitution; Drug Therapy, Combination; Female; Humans; Lower Urinary Tract Symptoms; Male; Medication Adherence; Middle Aged; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Symptom Assessment; Thiazoles; Time Factors; Urinary Bladder, Overactive; Urological Agents | 2019 |
The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Prospective Studies; Sexual Behavior; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Thiazoles; Urinary Bladder, Overactive | 2019 |
Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Benzhydryl Compounds; Cholinergic Antagonists; Female; Humans; Lasers, Solid-State; Middle Aged; Prospective Studies; Syndrome; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urologic Surgical Procedures; Vagina | 2019 |
Re: Safety and Therapeutic Efficacy of Mirabegron 25 mg in Older Patients with Overactive Bladder and Multiple Comorbidities.
Topics: Acetanilides; Humans; Thiazoles; Urinary Bladder, Overactive | 2019 |
Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2019 |
Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.
Topics: Acetanilides; Administration, Oral; Adult; Aged; Aged, 80 and over; Anxiety; Depression; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
Patient utilization survey of mirabegron prescribed for overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Quality of Life; Self Report; Thiazoles; Urinary Bladder, Overactive; Young Adult | 2019 |
Modulation of urinary frequency via type 1 lysophosphatidic acid receptors: Effect of the novel antagonist ASP6432 in conscious rats.
Topics: Animals; Benzamides; Consciousness; Dose-Response Relationship, Drug; Female; Rats; Rats, Sprague-Dawley; Receptors, Lysophosphatidic Acid; Thiazoles; Urinary Bladder, Overactive; Urination | 2019 |
Urodynamics as a Prognosticator of Mirabegron Treatment Outcomes.
Topics: Acetanilides; Adult; Aged; Diagnostic Techniques, Urological; Female; Humans; Middle Aged; Predictive Value of Tests; Prognosis; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents | 2019 |
[Value of mirabegron in the treatment of overactive bladder].
Topics: Acetanilides; Humans; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2019 |
Re: Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Topics: Acetanilides; Humans; Marketing; Thiazoles; Urinary Bladder, Overactive | 2019 |
Overactive bladder - pharmacological treatment.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Antidepressive Agents; Benzilates; Benzofurans; Brazil; Clinical Decision-Making; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Pyrrolidines; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Topics: Acetanilides; Adult; Benzhydryl Compounds; Cresols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Thiazoles; Urinary Bladder, Overactive | 2019 |
RE: Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2019 |
A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzofurans; Denmark; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Norway; Practice Patterns, Physicians'; Prospective Studies; Pyrrolidines; Registries; Solifenacin Succinate; Sweden; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2019 |
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
Topics: Acetanilides; Aged; Canada; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Registries; Surveys and Questionnaires; Thiazoles; Treatment Outcome; United States; Urinary Bladder, Overactive; Urological Agents | 2019 |
Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Age Factors; Aged; Aged, 80 and over; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2019 |
Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Topics: Acetanilides; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Reproducibility of Results; Surveys and Questionnaires; Symptom Assessment; Thiazoles; Translations; Treatment Outcome; Turkey; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2019 |
Mirabegron (Myrbetriq) for overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Interactions; Humans; Receptors, Adrenergic, beta-3; Thiazoles; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics | 2013 |
New drug update: 2012.
Topics: Acetanilides; Aged; Bronchodilator Agents; Constipation; Drug Approval; Glaucoma; Humans; Peptides; Prostaglandins F; Thiazoles; United States; Urinary Bladder, Overactive | 2013 |
Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport, Active; Caco-2 Cells; Cell Membrane Permeability; Female; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; LLC-PK1 Cells; Neoplasm Proteins; Oocytes; Organic Anion Transporters; Peptide Transporter 1; Recombinant Proteins; Swine; Symporters; Thiazoles; Urinary Bladder, Overactive; Xenopus laevis | 2013 |
Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron.
Topics: Acetanilides; Analysis of Variance; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Cresols; Data Interpretation, Statistical; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Psychometrics; Quality-Adjusted Life Years; Sickness Impact Profile; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2013 |
Editorial comment.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Thiazoles; Urinary Bladder, Overactive | 2013 |
Lower urinary tract dysfunction: From basic science to clinical management. Foreword.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Afferent Pathways; Biomarkers; Botulinum Toxins; Carbolines; Humans; Lower Urinary Tract Symptoms; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Thiazoles; Urinary Bladder, Overactive; Urothelium | 2013 |
Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cholesterol, Dietary; Chronic Disease; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Iliac Artery; Ischemia; Male; Neointima; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-3; Thiazoles; Time Factors; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Vascular System Injuries | 2013 |
Mirabegron for male lower urinary tract symptoms.
Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Humans; Lower Urinary Tract Symptoms; Male; Nocturia; Prostatic Hyperplasia; Prostatism; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2013 |
Urogynecology digest : presented by Fiona M. Lindo.
Topics: Acetanilides; Bariatric Surgery; Cystitis, Interstitial; Female; Gynecology; Humans; Muscarinic Antagonists; Obesity; Pelvic Floor Disorders; Thiazoles; Urinary Bladder, Overactive; Urology | 2014 |
Mirabegron for overactive bladder syndrome.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Female; Humans; Male; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2013 |
[Efficacy of mirabegron, a β3-adrenergic agonist, switched from an anticholinergic agent for female patients aged over 70 years].
Topics: Acetanilides; Adrenergic beta-2 Receptor Agonists; Age Factors; Aged; Aged, 80 and over; Cholinergic Antagonists; Drug Substitution; Female; Humans; Muscarinic Antagonists; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2013 |
Inaccuracies in the recently published review on mirabegron.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Thiazoles; Urinary Bladder, Overactive | 2014 |
Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP(1) receptor antagonists for treatment of overactive bladder by core structure replacement.
Topics: Animals; Drug Evaluation, Preclinical; Half-Life; Humans; Indazoles; Protein Binding; Rats; Receptors, Prostaglandin E, EP1 Subtype; Structure-Activity Relationship; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive | 2014 |
Re: β3-adrenoreceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Thiazoles; Urinary Bladder, Overactive | 2014 |
Words of wisdom. Re: Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
Topics: Acetanilides; Humans; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2014 |
Mirabegron the first β3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Thiazoles; Urinary Bladder, Overactive | 2014 |
Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?
Topics: Acetanilides; Acetylcholine Release Inhibitors; Administration, Intravesical; Adrenergic beta-3 Receptor Agonists; Aged; Botulinum Toxins, Type A; Female; Humans; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Retreatment; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive | 2015 |
Severity of symptoms of overactive bladder: a predictor of success and of failure.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence | 2015 |
Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Cost-Benefit Analysis; Health Services; Humans; Markov Chains; Muscarinic Antagonists; National Health Programs; Thiazoles; United Kingdom; Urinary Bladder, Overactive; Urological Agents | 2015 |
Role of spinal metabotropic glutamate receptor 5 in pudendal inhibition of the nociceptive bladder reflex in cats.
Topics: Acetic Acid; Action Potentials; Animals; Cats; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Male; Muscle Contraction; Muscle, Smooth; Nerve Fibers, Unmyelinated; Neural Inhibition; Nociception; Nociceptors; Pudendal Nerve; Pyridines; Receptor, Metabotropic Glutamate 5; Reflex; Signal Transduction; Spinal Cord Injuries; Spinal Nerves; Thiazoles; Thoracic Vertebrae; Time Factors; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2015 |
[Idiopathic overactive bladder: What to do in case of anticholinergic failure?].
Topics: Acetanilides; Acetylcholine Release Inhibitors; Adrenergic beta-3 Receptor Agonists; Botulinum Toxins, Type A; Cholinergic Antagonists; Humans; Thiazoles; Treatment Failure; Urinary Bladder, Overactive | 2015 |
The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cohort Studies; Electrocardiography; Female; Heart Rate; Humans; Middle Aged; Risk Factors; Thiazoles; Urinary Bladder, Overactive | 2015 |
Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2015 |
Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive | 2015 |
Mirabegron.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Neuromuscular Agents; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive | 2015 |
Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents | 2015 |
Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction: K. Ichihara, N. Masumori, F. Fukuta, T. Tsukamoto, A. Iwasawa and Y. Tanaka J U
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Humans; Male; Sulfonamides; Thiazoles; Urinary Bladder, Overactive | 2015 |
Reply by Authors.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Humans; Male; Sulfonamides; Thiazoles; Urinary Bladder, Overactive | 2015 |
Re: Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Ischemia; Male; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive | 2015 |
Drug therapy for an overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Cholinergic Antagonists; Comorbidity; Female; Humans; Medication Adherence; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urological Agents; Women's Health | 2015 |
[Persistence in the treatment of overactive bladder (OAB) with Mirabegron in a multicentre clinical study].
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Body Mass Index; Cholinergic Antagonists; Female; Humans; Male; Middle Aged; Patient Compliance; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2015 |
Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Diagnostic Techniques, Urological; Female; Humans; Middle Aged; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Patient Preference; Randomized Controlled Trials as Topic; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Xerostomia | 2015 |
Combination of solifenacin and mirabegron for overactive bladder management.
Topics: Acetanilides; Female; Humans; Male; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2015 |
Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Bayes Theorem; Comparative Effectiveness Research; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Health Resources; Humans; Markov Chains; Models, Economic; Muscarinic Antagonists; Patient Selection; Quality of Life; Quality-Adjusted Life Years; Severity of Illness Index; State Medicine; Thiazoles; Time Factors; Treatment Outcome; United Kingdom; Urinary Bladder; Urinary Bladder, Overactive | 2015 |
Mirabegron: A new option in treating overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Humans; Hypertension; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive | 2015 |
Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.
Topics: Acetanilides; Adult; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Spinal Cord Injuries; Statistics, Nonparametric; Switzerland; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2016 |
DFL23448, A Novel Transient Receptor Potential Melastin 8-Selective Ion Channel Antagonist, Modifies Bladder Function and Reduces Bladder Overactivity in Awake Rats.
Topics: Animals; Behavior, Animal; Cold Temperature; Dinoprostone; Female; Half-Life; HEK293 Cells; Humans; Male; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Tetrazoles; Thiazoles; TRPM Cation Channels; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics | 2016 |
Persistence with mirabegron therapy for overactive bladder: A real life experience.
Topics: Acetanilides; Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Male; Middle Aged; Patient Satisfaction; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2017 |
Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females.
Topics: Acetanilides; Aged; Body Mass Index; Female; Humans; Middle Aged; Risk Factors; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
Tolerability and persistence in a large, prospective case series of women prescribed mirabegron.
Topics: Acetanilides; Adult; Aged; Cholinergic Antagonists; Drug Therapy, Combination; Female; Humans; Medication Adherence; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Female; Humans; Male; Muscarinic Antagonists; Off-Label Use; Patient Satisfaction; Pilot Projects; Prospective Studies; Retreatment; Surveys and Questionnaires; Thiazoles; Treatment Failure; Urinary Bladder, Overactive; Urinary Incontinence | 2016 |
The efficacy and tolerability of mirabegron in a non-trial clinical setting.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Female; Humans; Middle Aged; Prospective Studies; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2016 |
Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
Topics: Acetanilides; Benzhydryl Compounds; Cost-Benefit Analysis; Delivery of Health Care; Female; Humans; Male; Middle Aged; Spain; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2016 |
Incontinence: Adding mirabegron to solifenacin improves patient outcomes.
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2016 |
Re: A Randomized, Controlled Trial of Effectiveness and Safety of Management of OAB Symptoms in Elderly Men and Women with Standard-Dosed Combination of Solifenacin and Mirabegron.
Topics: Acetanilides; Aged; Female; Humans; Male; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Cardiovascular Diseases; Cohort Studies; Drug Monitoring; Female; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Outpatient Clinics, Hospital; Prospective Studies; Quality of Life; Risk; Self Report; Severity of Illness Index; Sweden; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2016 |
Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
Topics: Acetanilides; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Humans; Male; Markov Chains; Medicare Part C; Muscarinic Antagonists; Thiazoles; United States; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2016 |
Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Contraceptives, Oral, Combined; Digoxin; Double-Blind Method; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Metformin; Thiazoles; Urinary Bladder, Overactive; Warfarin | 2017 |
Combined treatment with a β
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cold Temperature; Disease Models, Animal; Drug Therapy, Combination; Female; Muscarinic Antagonists; Rats; Rats, Inbred SHR; Solifenacin Succinate; Stress, Physiological; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents | 2017 |
The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Hormonal influence on the effect of mirabegron treatment for overactive bladder.
Topics: Acetanilides; Aged; Dose-Response Relationship, Drug; Estradiol; Female; Follow-Up Studies; Gonadotropins; Humans; Logistic Models; Middle Aged; Prospective Studies; Testosterone; Thiazoles; Thyroid Hormones; Urinary Bladder, Overactive; Urological Agents | 2016 |
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Topics: Acetanilides; Double-Blind Method; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Budgets; Health Care Costs; Humans; Insurance, Health; Medicare Part C; Middle Aged; Muscarinic Antagonists; Thiazoles; Treatment Outcome; United States; Urinary Bladder, Overactive; Urological Agents | 2016 |
Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
Topics: Acetanilides; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Patient Safety; Prospective Studies; Sulfonamides; Tamsulosin; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents | 2016 |
Neurotransmitter Mechanisms Underlying Sacral Neuromodulation of Bladder Overactivity in Cats.
Topics: Acetic Acid; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Cats; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Indicators and Reagents; Male; Naloxone; Narcotic Antagonists; Neurotransmitter Agents; Propranolol; Pyridines; Sacrum; Spinal Cord Stimulation; Spinal Nerve Roots; Thiazoles; Urinary Bladder, Overactive | 2017 |
Re: Cardiovascular Safety of β3-Adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Receptors, Adrenergic; Thiazoles; Urinary Bladder, Overactive | 2016 |
Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Body Weight; Carbachol; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle Contraction; Muscle, Smooth; Obesity; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urination | 2017 |
High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Drug Substitution; Female; Humans; Male; Muscarinic Antagonists; Patient Satisfaction; Thiazoles; Urinary Bladder, Overactive | 2016 |
Re: The Efficacy of Mirabegron Additional Therapy for Lower Urinary Tract Symptoms after Treatment with Α1-Adrenergic Receptor Blocker Monotherapy: Prospective Analysis of Elderly Men.
Topics: Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Aged; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Receptors, Adrenergic; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Diabetes Complications; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Retention; Urological Agents | 2018 |
Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2017 |
Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Humans; Middle Aged; Prospective Studies; Thiazoles; Urinary Bladder, Overactive | 2017 |
Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Analysis of Variance; Drug Substitution; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Topics: Acetanilides; Aged; Benzhydryl Compounds; Cross-Sectional Studies; Drug Utilization; Female; Health Care Costs; Health Expenditures; Humans; Male; Managed Care Programs; Medicare; Muscarinic Antagonists; Retrospective Studies; Thiazoles; United States; Urinary Bladder, Overactive; Urological Agents | 2017 |
Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Thiazoles; Urinary Bladder, Overactive; Young Adult | 2017 |
Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Databases, Factual; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Thiazoles; Time Factors; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2017 |
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-Blind Multicentre Phase 3B Study (BESIDE).
Topics: Acetanilides; Double-Blind Method; Humans; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive | 2017 |
Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.
Topics: Acetanilides; Cholinergic Antagonists; Humans; Quality of Life; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urination; Urological Agents | 2017 |
[Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care].
Topics: Acetanilides; Costs and Cost Analysis; Delivery of Health Care; Humans; Models, Economic; Russia; Thiazoles; Urinary Bladder, Overactive | 2016 |
Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
Topics: Acetanilides; Canada; Humans; Medication Adherence; Models, Econometric; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urological Agents | 2017 |
Mirabegron for the treatment of overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Interactions; Humans; Thiazoles; Urinary Bladder, Overactive | 2012 |
Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Female; Infusions, Intravenous; Muscarinic Antagonists; Phenylpropanolamine; Rats; Rats, Sprague-Dawley; Thiazoles; Tolterodine Tartrate; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urination | 2012 |
Overactive bladder, under scrutiny, gets a new treatment.
Topics: Acetanilides; Adrenergic beta-Agonists; Drug Approval; Humans; Receptors, Adrenergic, beta-3; Thiazoles; United States; United States Food and Drug Administration; Urinary Bladder, Overactive | 2012 |
Mirabegron for overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Interactions; Humans; Thiazoles; Urinary Bladder, Overactive | 2012 |
Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Benzhydryl Compounds; Cresols; Female; Humans; Male; Muscarinic Antagonists; Phenylpropanolamine; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive | 2013 |
Elvitegravir/cobicistat, mirabegron, and linaclotide.
Topics: Acetanilides; Adenine; Anti-Retroviral Agents; Carbamates; Constipation; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Peptides; Quinolones; Thiazoles; Urinary Bladder, Overactive | 2012 |
In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cerebral Infarction; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Male; Muscle, Smooth; Rats; Rats, Wistar; Receptors, Adrenergic, beta-3; Thiazoles; Transfection; Urinary Bladder; Urinary Bladder, Overactive | 2013 |
The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Carbachol; Humans; In Vitro Techniques; Inhibitory Concentration 50; Isoproterenol; Male; Middle Aged; Muscle Contraction; Thiazoles; Urinary Bladder; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2013 |
Treating overactive bladder: a new tool in your toolkit.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Drug Therapy, Combination; Humans; Thiazoles; Urinary Bladder, Overactive | 2012 |
Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Aprepitant; Female; Humans; Morpholines; Pyrazoles; Receptors, Neurokinin-1; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2009 |